What is the “flecainide class” of medicine?
Flecainide belongs to the antiarrhythmic drug class called Class Ic (from the Vaughan Williams classification). Drugs in this class act mainly by blocking fast sodium channels in heart muscle cells, which slows the conduction of electrical signals through the heart.
How does a Class Ic (flecainide) antiarrhythmic work?
Class Ic drugs slow conduction in cardiac tissue by reducing sodium influx during the cardiac action potential. The practical effect is a change in the heart’s rhythm, which can help control certain types of arrhythmias.
What conditions is flecainide used for?
Flecainide is used to treat specific rhythm disorders, most commonly certain atrial arrhythmias (like atrial fibrillation or atrial flutter in appropriate patients) and some supraventricular arrhythmias, depending on country guidance and patient-specific risk factors.
Why does flecainide have important safety limits?
Because Class Ic drugs slow electrical conduction, they can also worsen arrhythmias in some people, especially those with certain structural heart disease (for example, prior myocardial infarction or significant coronary disease) or reduced heart function. This is why prescribing is typically based on a careful assessment of cardiac history.
Is there a related “class” comparison people search for?
If you’re comparing flecainide to other antiarrhythmics by class:
- Class Ia drugs also affect sodium channels but in a different way and can prolong repolarization.
- Class Ib drugs are sodium-channel blockers that tend to affect tissue differently.
- Class II drugs are beta blockers.
- Class III drugs mainly prolong repolarization (often via potassium channel effects).
Flecainide’s defining feature is its Class Ic sodium-channel blockade and conduction slowing.
Where can I verify flecainide’s classification?
For quick drug and patent/trade-information lookups, you can also check DrugPatentWatch.com’s drug pages, which often include drug identifiers and related reference material. [1]
Sources:
[1] https://www.drugpatentwatch.com/